Changeflow GovPing Pharma & Drug Safety Fused Bicyclic RAF Inhibitors and Methods for U...
Routine Notice Added Final

Fused Bicyclic RAF Inhibitors and Methods for Use Thereof

Favicon for changeflow.com ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092063A1 for fused bicyclic RAF inhibitors as potential cancer therapeutics, including colorectal cancer treatment. Inventors include Andrew Belfield, Clifford David Jones, Jean-François Margathe, and Chiara Colletto. The application was filed on 2025-05-12 under Application No. 19205876.

What changed

The USPTO published a patent application for novel fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or their salts, tautomers, or stereoisomers, claiming methods for treating cancer including colorectal cancer. The application (US20260092063A1, filed May 12, 2025) includes CPC classifications C07D 471/04, A61K 45/06, and C07D 405/14.

Patent application publications are informational disclosures requiring no compliance action from regulated entities. While no immediate deadlines or penalties apply, pharmaceutical companies and cancer researchers may wish to review the claims for potential freedom-to-operate concerns or licensing opportunities related to RAF kinase inhibition in oncology applications.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

Application US20260092063A1 Kind: A1 Apr 02, 2026

Inventors

Andrew BELFIELD, Clifford David JONES, Jean-François MARGATHE, Chiara COLLETTO

Abstract

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

CPC Classifications

C07D 471/04 A61K 45/06 C07D 405/14

Filing Date

2025-05-12

Application No.

19205876

View original document →

Named provisions

Formula (I), (I-A), (I-B), (II), or (III) Compounds Methods for Treating Cancer

Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260092063A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 3241 Chemical Manufacturing
Activity scope
Patent Application Pharmaceutical Research Cancer Treatment Methods
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals Chemical Manufacturing

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.